Short Interest in Curanex Pharmaceuticals Inc (NASDAQ:CURX) Declines By 43.2%

Curanex Pharmaceuticals Inc (NASDAQ:CURX) saw a large drop in short interest in July. As of July 15th, there was short interest totaling 11,829 shares, a drop of 43.2% from the June 30th total of 20,835 shares. Based on an average daily volume of 81,338 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the shares of the stock are sold short.

Curanex Pharmaceuticals Stock Down 3.0%

Shares of Curanex Pharmaceuticals stock traded down $0.01 during trading on Wednesday, hitting $0.19. The stock had a trading volume of 12,197 shares, compared to its average volume of 1,939,257. The company has a market capitalization of $5.45 million and a PE ratio of -0.71. Curanex Pharmaceuticals has a 1 year low of $0.18 and a 1 year high of $9.18. The stock has a 50 day simple moving average of $0.27 and a 200 day simple moving average of $0.35.

Curanex Pharmaceuticals (NASDAQ:CURX) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter.

Institutional Investors Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new position in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 64,067 shares of the company’s stock, valued at approximately $46,000.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.